GSK goes to phase II with German Antibody for Inflammatory Diseases

19/04/2016 - 2 minutes

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. 

gsk_morphosys_auto-immune_anti_gm_csfGSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165.

The trial will enroll 40 patients with hand osteoarthritis – a condition that damages joints, leading to pain and stiffness.

GSK3196165 is a monoclonal antibody that acts as anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF). GM-CSF is a protein secreted by cells of the immune system, involved in cell signalling and inflammatory response.

Therapies based on GM-CSF are also used in immuno-oncology. Amgen (US) used this biological target as an oncolytic therapy for melanoma and Transgene (France) is in phase III trials for liver cancer.

The monoclonal antibody now in trials was actually discovered and engineered by MorphoSys, being licensed to GSK in 2013.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member